Figure 7.

Changes in plasma VEGF-A (ratio to baseline VEGF-A) according to clinical benefit during the first two treatment cycles and at the time of later progression (for patients that initially obtained a clinical benefit). CB: Clinical benefit; PD: Disease progression

Kontovinis et al. BMC Cancer 2009 9:82   doi:10.1186/1471-2407-9-82
Download authors' original image